ClinicalTrials.gg
RecruitingNCT04743791Updated Aug 6, 2026

Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma

A Phase 4 interventional study of Dupilumab and Placebo in Asthma, sponsored by Sally E. Wenzel MD. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Sally E. Wenzel MD · Phase 4, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.

Planned enrollment
27th of 31
30 · median 120
Started
2022
with 3 others
Phase 4
14 of 31
5 open now
Primary completion
2027-12
later than 8 of 11 live
Registered
19th of 31
by date
Lead sponsor
1 of 31
Sally E. Wenzel MD

Among the 31 studies testing dupilumab in Asthma, this one is the 27th largest by planned enrollment, is one of 4 that started in 2022, is one of 14 in phase 4, reaches primary completion later than 8 of the 11 other live ones, and was the 19th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing dupilumab in Asthma, or all of them as a file.
02

Study summary

Single center, randomized, placebo- controlled study to assess change in mucociliary clearance of moderate to severe asthma patients after treatment with dupilumab or placebo.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderate - Severe Th2 (Type 2) High asthma, as defined by (FEV1) \<90% predicted, on medium to high dose inhaled (ICS) with or without a second controller
  • Age > 18
  • Inhaled steroid doses of 500micrograms (mcg) per day or more (Fluticasone equivalent)
  • Reversibility >/= 12% at screening or within the past 2 years, or a positive methacholine challenge test within the past 2 years, or a positive methacholine challenge during screening
  • FEV1/Forced Vital Capacity (FVC)\<75%
  • Blood Eosinophils (EOS) >300 cells per mm3
  • Exhaled Nitric Oxide (FeNO) >25 parts per billion (ppb)
  • Asthma Control Test (ACT) score \<20

Exclusion criteria

Exclusion Criteria:

  • Pregnant, nursing, or unwilling to test for pregnancy
  • Current smoker or >10 pack year smoking history
  • (BMI)>37
  • Respiratory infection in the last 30 days
  • Use of antibiotics or oral prednisone in the last 30 days
  • Current or previous use of dupilumab
  • Current or recent use of anti-IL-5 therapies
  • Any other criteria that place the subject at unnecessary risk
  • Diagnosis of other lung diseases including (COPD)
  • History of non-skin cell cancer in the last 5 years
  • Drug or alcohol addiction in the last 5 years
  • Any other uncontrolled disease
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Dupilumab

    Two injections of Dupilumab will be administered at Week 0/Visit 3 as a loading dose. Subsequently one injection of Dupilumab will be given every 2 weeks ± 3 days at home by the patient. The doses of investigational product must be separated by ≥11 days to avoid an overdose.

    Drug: Dupilumab

  • Placebo comparator
    Placebo

    Two injections of placebo will be administered at Week 0/Visit 3 as a loading dose. Subsequently one injection of placebo will be given every 2 weeks ± 3 days at home by the patient. The doses must be separated by ≥11 day.

    Other: Placebo

Interventions

  • Dupilumab is supplied as a sterile aqueous solution for SC injection at the concentration of 175 mg/mL in glass pre-filled syringe to deliver 200 mg in 1.14mL.

  • OtherPlacebo

    Sterile placebo for dupilumab will be provided in identically matched glass pre-filled syringe to deliver 200 mg in 1.14mL, which will match dupilumab 200 mg (1.14mL).

    Also known as: Sucrose

06

What researchers measure

Primary outcomes

  1. Change in mucociliary clearance (MCC) rate

    MCC is measured using an aerosol-based nuclear imaging technique

    Time frame: Measured at 12 weeks after the start of treatment

Secondary outcomes

  1. Change in FEV1% predicted

    Assessed using spirometry after bronchodilator administration.

    Time frame: Measured from baseline to 12 weeks after start of treatment

  2. Change in ACT score

    Measured via the Asthma Control Test questionnaire. Scores range from 5 (poor control of asthma) to 25 (complete control of asthma).

    Time frame: Measured from baseline to 12 weeks after start of treatment

  3. Change in sputum eosinophils and T2 gene mean

    Measured via sputum induction to obtain airway cells and fluid from patients.

    Time frame: Measured from baseline to 12 weeks after start of treatment

  4. Change in mucus plugging score by CT

    Radiologists will visually assess the presence or absence of mucus plugging in segmental airways and will provide a mucus plugging score

    Time frame: Measured from baseline to 12 weeks after start of treatment

  5. Whole lung MCC90, AAC90

    Measured via mucociliary clearance imaging

    Time frame: Measured from baseline to 12 weeks after start of treatment

  6. Peripheral and central lung MCC90, MCC240, AAC90

    Measured via mucociliary clearance imaging

    Time frame: Measured from baseline to 12 weeks after start of treatment

07

Study locations

1 of 1 sites recruiting
  • The University of Pittsburgh Asthma Institute at UPMC
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Dec 2027, 62 months after the start.

Of 90 non-industry phase 4 interventional studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's planned 62 months is above that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2021
First posted
Feb 8, 2021
StartActual
Oct 17, 2022
Primary completionEst.
Dec 2027
CompletionEst.
Jun 2028
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04743791
Lead sponsor
Sally E. Wenzel MD
Responsible party
Sally E. Wenzel MD (Professor, University of Pittsburgh) — Sponsor-investigator
First posted
Feb 8, 2021
Start date
Oct 17, 2022
Primary completion
Dec 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Aug 6, 2026

Study contacts

John Moore
Contact
mooreja6@upmc.edu
412-648-6726

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion